Miracor Medical Systems (Austria) a development-stage medical device company focused on acute coronary syndrome and heart failure, closed a $10M Series B financing. Participants include Austria Wirtschaftsservice, SHS, Earlybird and Delta Partners.

AM-Pharma (The Netherlands) a clinical-stage pharmaceutical company focused on acute kidney injury and ulcerative colitis, closed a $39.8M Series D financing. Participants include Ysios Capital Partners, Kurma Life Science Partners, Abbott Ventures, Shire Ventures, BB Biotech Ventures, Idinvest Partners, Forbion Capital Partners and Inventages Venture Capital.

Amakem (Belgium) a development-stage pharmaceutical company focused on glaucoma and other ophthalmic indications, closed a $25.3M Series A financing. Participants include Forbion Capital Partners, Crédit Agricole Private Equity, Vesalius BioCapital and Life Sciences Research Partners.

Milestone Pharmaceuticals (Canada) a development-stage pharmaceutical company focused on small molecules for atrial arrhythmias and angina, closed a $13M Series B financing. Participants include Pappas Ventures, GO Capital, Fonds de solidarité FTQ, iNovia Healthcare Ventures and Fonds Bio-Innovation.
The 2Q11 OnBioVC Trend Analysis will be published on Tue 6 September. Advertising opportunities are still available. Reach [...]

Enerkem (Canada) a development-stage waste-to-biofuels and chemicals company, closes a $60M Series C financing. Participants include Valero Energy, Waste Management, Rho Ventures, Braemar Energy Ventures and Cycle Capital.
The 2Q11 OnBioVC Trend Analysis will be published on Tue 6 September. Advertising opportunities are still available. Reach >45,000 high-value targeted life science professionals on-line and in-print. Contact [...]

Avantium (Netherlands) a commercial-stage clinical research organization focused on high-throughput R&D, closed a $36.2M Series B financing. Participants include Sofinnova Partners, Aster Capital, De Hoge Dennen, Aescap Venture, Capricorn Cleantech Fund, ING Corporate Investments and Navitas Capital.
The 2Q11 OnBioVC Trend Analysis will be published on Tue 6 September. Advertising opportunities are still available. Reach [...]

Shield Therapeutics (United Kingdom) a clinical-stage pharmaceutical company focused on inflammatory bowel disease, closed a$12M Series A financing. Participants include Inventages Venture Capital.

Trillium Therapeutics (Canada) a preclinical-stage biopharmaceutical company focused on interstitial cystitis, closed a $1M Series A financing. Participants include BDC Venture Capital.

Stabilitech (United Kingdom) a development-stage medical device company focused on a thermal stabilization technology to store vaccines and biopharmaceuticals, closed a $3.5M Series C financing. Participants were not identified.

ProFibrix (Netherlands) a clinical-stage company focused on blood clotting and tissue healting, closed a $10.6M Series B financing, bringing the total round to $21.6M. Participants include Gilde Healthcare Partners and Index Ventures.

OrSense (Israel) a commercial-stage medical device company focused on non-invasive measurements of oxygen saturation, hemoglobin, glucose and other blood parameters, closed $18M Series D financing. Participants include Israel HealthCare Ventures, Star Ventures and Lewis Trust Private Equity.

Caprotec Bioanalytics (Germany) a commercial-stage biopharmaceutical company focused on a capture compound mass spectrometry technology based on multifunctional small molecules used to target, capture, and isolate proteins, closed a $1.4M Series B financing, bringing the total round to $7.2M. Participants include LBBW Venture Capital, Creathor Venture, IBB Beteiligungsgesellschaft and ERP Startfonds.

Nexstim (Finland) a commercial-stage developer of non-invasive brain imaging technologies focused on cortical mapping prior to surgery, closed a $2.8M Series D financing, bringing the total round to $19.2M. Participants include Capricorn Health-tech Fund, Tekes, HealthCap, Sitra, Finnish Industry Investment, Lundbeckfond Ventures and Ilmarinen.